AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06650332
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m\\(\^2\\), IV, d1; Leucovorin (folinic acid) 400 mg/m\\(\^2\\), IV, d1; 5-FU 400 mg/m\\(\^2\\), IV, d1, followed by 2400 mg/m\\(\^2\\), continuous intravenous infusion over 46 hours.
Trial: NCT06333600
Drug: Saline spray
RxNorm normalized name: Saline Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT05254977
Drug: Standard Preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any kind of intervention received to reduce adverse effects
Trial: NCT05963022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04349826
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 20 mg/kg/day for 7 days
Trial: NCT04349826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefixime-matched placebo for 7 days
Trial: NCT05266729
Drug: Polyene Phosphatidylcholine
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
Trial: NCT05266729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection
Trial: NCT06147856
Drug: mRNA-3210
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06054750
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
Trial: NCT05532293
Drug: MSP008-22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSP008-22 is a small molecule with demonstrated anticancer activity in-vitro \& in vivo studies. As several anticancer drugs are also good antiviral drugs, it was anticipated that MSP008-22 can also be a promising anti-COVID drug. Accordingly, in vitro assay studies and in an in vivo study in golden Syrian hamster were conducted where MSP008-22 has shown good anti-SARSCoV2 effects.MSP008-22.
Trial: NCT05069870
Drug: SKLB1028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKLB1028, capsule, oral
Trial: NCT06532240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An identical volume of 5% dextrose solution from the placebo drug bag will be administered to patients using the same protocol as intervention arm.
Trial: NCT06231771
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage · Dosing of placebo is based on ulcer size. the volume will be samed as the experimental groups which is 2 ml per 1cm2 Administration · Injections will be done through peri-ulcer route. · Injection will be done 0.75 cm from the edge of the ulcer. · Injection will be done using 24G. The volume of injection will 4.0 - 6.0 ml per patient (maximum 0.1 to 0.2 ml per injection; 30 injections maximum per patients)
Trial: NCT03998852
Drug: Positron Emission Tomography (PET) with [18F]-FEOBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positron Emission Tomography (PET) with \[18F\]-FEOBV
Trial: NCT05867329
Drug: Intravenous Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug will be administered as 30mg twice daily during the first stage of treatment (if applicable) and through the second stage of treatment (if applicable). Prior to discharge a patient will be switched from IV Methylprednisolone to prednisone 40-60mg with plans to taper by 5mg/week (dose subject to adjustment by treating inpatient team and in consultation with the outpatient gastroenterologist).
Trial: NCT05296369
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid was added during the period prior to concurrent chemoradiotherapy
Trial: NCT06043544
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in control group received two intra-articular injections with corticosteroids a week apart from each other.
Trial: NCT05563155
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet given on day 1 after surgery.
Trial: NCT06056323
Drug: HB0045 Drug Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.
Trial: NCT06099080
Drug: SM-020 gel 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will apply the investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12 weeks post final application for a total of approximately 16 weeks of required participation in the study.
Trial: NCT05822765
Drug: Epinephrine concentration of 1:1000000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescence fluid contained Epinephrine concentration of 1:1000000 (one ampoule 1 mg per liter) lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
Trial: NCT05822765
Drug: Epinephrine concentration of 1:500000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumescence fluid contained Epinephrine concentration of 1:500000 two ampoule 2 mg/liter with same lidocaine and bicarbonate dose. lidocaine 500 mg and sodium bicarbonate 8.4% 10 ml per liter
Trial: NCT06652139
Drug: BEAM regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carmustine: 300mg/m2 ivgtt D-8 Etoposide: 100mg/m2/d ivgtt q12h D-7-D-4 Cytarabine: 200mg/m2/d ivgtt q12h D-7-D-4 Melphalan: 140mg/m2 ivgtt D-3-D2
Trial: NCT00465322
Drug: fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05533229
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The trial aims to study the quality of anesthesia and perioperative analgesia and patient's satisfaction provided by fentanyl and bupivacaine versus morphine and bupivacaine.
Trial: NCT05901389
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the thoracoscopic surgery, normal saline will be transfused through the epidural tube fixed in the chest drainage tube was connected to an electronic pump whose parameters are already set up (marking the chest drain for analgesia).
Trial: NCT05908643
Drug: pTTL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pTTL is an autologous cell product for adoptive cancer immunotherapy containing in vitro expanded T cells stimulated with patient-specific tumour neoantigens derived from tumour-draining lymph nodes.
Trial: NCT03917407
Drug: DUR-928 (Moderate AH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.
Trial: NCT03917407
Drug: DUR-928 (Severe AH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~* Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~* Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study.
Trial: NCT05292339
Drug: Ketorolac injection to the shoulder, elbow, wrist, or hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation by inhibiting Cyclo-oxygenase (COX)-2 dependent prostaglandin release via the cyclooxygenase pathway.
Trial: NCT05542173
Drug: BALI association
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BALI association oral suspension, 25 mg + 25 mg + 15 mg, oral. Three applications per day or more in case of pain, not exceeding six applications per day.
Trial: NCT05542173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo. Three applications per day or more in case of pain, not exceeding six applications per day.
Trial: NCT05323058
Drug: tulsi extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% topical oral spray
Trial: NCT00000659
Drug: CD4 Antigens
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05637060
Drug: Test Drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose of Vaptor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Trial: NCT05637060
Drug: Reference Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single dose of Crestor 20 mg will be administered to subjects after at least 10 hours fast together with 240 mL of ambient temperature water at their scheduled dosing time.
Trial: NCT06326983
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (12.5mg/kg with a maximum dose of 1 gram given intravenously at induction of anesthesia).
Trial: NCT06326983
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.5mg/kg with a max dose of 30mg intravenously at the end of surgery.
Trial: NCT05654077
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
Trial: NCT05792735
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2400 mg/m2 for 48 h) every 2 weeks for total 6 cycles preoperatively and postoperatively.
Trial: NCT04637282
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taste and color-matched drug-free solution
Trial: NCT06439277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06008015
Drug: BR1015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06008015
Drug: BR1015-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT06008015
Drug: BR1015-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone
Trial: NCT04959175
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-transplant: 14.5 mg/kg/day IV daily for 2 days pre-transplant (Pre-Transplant days -6 and -5). Post-transplant: 25 mg/kg/day or 35 mg/kg/day (Post-transplant days +3 and +4).
Trial: NCT06572228
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by SC injection
Trial: NCT06572228
Drug: ICS/LABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered at a blinded dose
Trial: NCT06566248
Drug: Placebo+NUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUC:~Entecavir Dispersible Tablets, Inhibit viral replication; Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors; Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication.
Trial: NCT04547439
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 3 mg will be taken nightly for 8 weeks
Trial: NCT00000724
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04404192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal administration of 100 microliters to each nostril 4 times a day.
Trial: NCT05107128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-718-matching oral capsules.
Trial: NCT06649656
Drug: TQB2252 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.
Trial: NCT05799248
Drug: rhPSMA-7.3 (18F)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a dose with an administered activity of 8 mCi (296 MBq) ± 20% of rhPSMA-7.3, delivered as an IV bolus injection with a 10 mL fast 0.9% sodium chloride flush, followed by PET imaging.
Trial: NCT05145218
Drug: TQB2450 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a programmed cell death protein 1 (PD-1) humanized monoclonal antibody.
Trial: NCT05219513
Drug: RO7443904
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7443904 will be administered by subcutaneous (SC) or IV infusion on Cycle (C) 1 Day (D) 10, C2D3, and C2D8. From C3 onward, RO7443904 will be given every 3 weeks (Q3W), for up to 12 cycles (C = 21 days).
Trial: NCT06475105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized into group receiving either oral acetazolamide or placebo for up to 3 days
Trial: NCT05401032
Drug: 5-hidroxitriptophan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication, 3 times a day for 6 months.
Trial: NCT05412446
Drug: ADAPT6-SPECT
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic SPECT for HER2 expression in primary tumour and metastatic lymph nodes
Trial: NCT06495632
Drug: Motrin and narcotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See described earlier
Trial: NCT06653738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily per os for 3 years
Trial: NCT03935451
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
Trial: NCT05664074
Drug: Rectal indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage based on subject's weight:~\>=50 kg, 100 mg; 30-49 kg, 50 mg; 10-29 kg, 25 mg
Trial: NCT05664074
Drug: IV ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage based on subject's weight: 0.5 mg/kg (maximum: 15 mg)
Trial: NCT05529095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sugar pill)
Trial: NCT00004845
Drug: Rofecoxib
RxNorm normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004845
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06374043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05354453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05148195
Drug: BD0801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
Trial: NCT05148195
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m2，Q2W
Trial: NCT05050279
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT06507059
Drug: Antiretroviral Combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard all-oral antiretroviral combinations
Trial: NCT05254847
Drug: Capecitabine combined with lenvatinib and tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine combined with lenvatinib and tislelizumab
Trial: NCT04723303
Drug: Umbilical Cord Lining Stem Cells
RxNorm normalized name: Bos taurus umbilical cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An IV infusion of ULSCs will be administered.
Trial: NCT04716712
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin is a macrolide-type antibiotic that is used to treat various types of infections. Previous studies in Niger have demonstrated a nearly 18% reduction in all-cause child mortality following biannual mass administration to children 1-59 months.
Trial: NCT04716712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching identical placebo in packaging, appearance, and taste.
Trial: NCT06317064
Drug: Ibuprofen and Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days.
Trial: NCT05312892
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00291213
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06535230
Drug: Manual anesthesia induction
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In manual anesthesia induction, anesthetic agents are administered at a fixed dose and rate adjusted according to the patient's weight
Trial: NCT06535230
Drug: Anesthesia induction with Target controlled infusions (TCI)
RxNorm normalized name: Marcaine with Epinephrine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target controlled infusion (TCI) system aims to reach the theoretically targeted blood or brain concentration of anesthetic agents based on the patient's age, weight, and height, with computer-assisted algorithms.
Trial: NCT00121043
Drug: Kineret® (Anakinra)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04510428
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Eye Drops (0.9% NaCl) four times a day for 8 weeks
Trial: NCT06540352
Drug: 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug Refralon® (n-1-\[(4-fluorophenyl)-2-(1-ethyl-4-piperidyl)-ethyl\]-4-nitrobenzamide hydrochloride) in the dosage form of a concentrate for the preparation of a solution for intravenous administration is registered for medical use in RF June 24, 2014, re-registration was successfully completed on November 20, 2019, registration certificate LP 002510, until December 31, 2025.
Trial: NCT04945226
Drug: IVL3001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride long acting injection
Trial: NCT06150664
Drug: CTX-8371
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion (0.1-10.0 mg/kg) every two weeks.
Trial: NCT05804123
Drug: 0.9% NaCl physiological saline Nasal-spraying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Trial: NCT06435065
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIRECT PULP CAPPINGWILL BE DONE USING BIODENTINE
Trial: NCT06435065
Drug: THERACAL LC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIRECT PULP CAPPINGWILL BE DONE USING THERACAL LC
Trial: NCT06435065
Drug: TRISTRONTIUM ALUMINATE
RxNorm normalized name: bismuth aluminate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIRECT PULP CAPPINGWILL BE DONE USING TRISTRONTIUM ALUMINATE
Trial: NCT05098262
Drug: DA-5210 10/500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05098262
Drug: DA-5210-R 10/500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose administration (one tablet once a day)
Trial: NCT05870800
Drug: Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled Participant will receive 4 cycles of neoadjuvant Atezolizumab (Tecentriq) followed by CAPEOX chemotherapy prior to surgery. Each cycle is every 3 weeks. (12 weeks)